Private Market View

MTE Biotech

Lincoln, NE · Founded 2016 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
$1.3M
Last round

Key facts

  • It has raised $1.3M; the latest was Angel (individual) ($750K) in Oct 2024.
  • Notable investors include Invest Nebraska, MOVE Venture Capital, Nelnet Ventures, The Combine (Nebraska).
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 4 names
  • ·Watchlist + deal alerts for MTE Biotech
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for MTE Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About MTE Biotech

Developer of a molecular trait technology designed to produce enzymes and chemicals from agricultural and municipal waste. The company's tech thrives at the limits of life under conditions that mimic biofuel processing, generate biofuels and renewable chemicals from agricultural waste, turning low-value starting materials into high-value renewable resources without competing with food or feed, enabling users to increase their product yields and growth profit margin.

Sector
Healthcare
HQ
Lincoln, NE, United States
Founded
2016
Employees
2
Ownership
Privately Held (backing)
PA Mark — not yet priced

MTE Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in MTE Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on MTE Biotech in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.